 |
13 Diseases |  |
52 Trials |
|
52 Trials |  |
3235 News |  |
| «12...2324252627282930313233...3637» |
- ||| Durva for PACIFIC is restricted to PD-L1>1%? Osi was restricted for long time but daco not. What about entrectinib/brigatinib/alectinib/selpercatinib/capmatinib (curious there I truly don’t know) (Twitter) - Jun 22, 2020
- || Alecensa (alectinib) / Roche
Don't know why we don't just have primary endpoint be blood levels of alectinib. It's about as challenging and similarly informative. Fortunately, oncs who just want a pretense to do what they want to do will hail it as a miracle. (Twitter) - Jun 19, 2020
- ||| Alecensa (alectinib) / Roche
Clinical: Patients respond very well to alectinib in the metastatic setting, so I don't think you can argue unethical with close monitoring (Twitter) - Jun 19, 2020
- |||| Retevmo (selpercatinib) / Eli Lilly, Alecensa (alectinib) / Roche
Clinical: You got it, another sure-fire winner for a DFS primary endpoint although if ADAURA has OS benefit I am not sure we need randomized trials for each different driver oncogene-driven NSCLC subtype if there are comparably good TKIs (like alectinib, selpercatinib, etc) #LCSM (Twitter) - Jun 19, 2020
- |||| Keytruda (pembrolizumab) / Merck (MSD), Alecensa (alectinib) / Roche
Checkpoint inhibition: 2 of these 5 are oncogene drugs tested against control arms that the same experts had abandoned for alectinib and osi 🤦 & they use a surrogate If doctors are appropriately giving Pembrolizumab, which they are, the checkpoint inhibitor approvals don't move the puck forward (Twitter) - Jun 15, 2020
- ||| Journal, Adverse events: Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database. (Pubmed Central) - Jun 13, 2020
Our results showed that patients who receive gefitinib or erlotinib should be closely monitored for the development of drug-induced interstitial lung disease within a short duration (4 weeks). In addition, elderly people who receive amiodarone or sho-saiko-to should be carefully monitored for the development of drug-induced interstitial lung disease.
- ||| Alecensa (alectinib) / Roche
Interestingly, we could have the discussion with ALKr NSCLC about alectinib tomorrow, but we don't Without a DFS benefit, there is no discussion; With DFS benefit, there is a discussion But why should the pt's autonomy be curtailed based on an un-validated surrogate? (Twitter) - Jun 12, 2020
- ||| Balversa (erdafitinib) / J&J, Otsuka, Pemazyre (pemigatinib) / Incyte, Alecensa (alectinib) / Roche
Clinical: To be fair, you could even say this for a drug that does not have a trial showing DFS benefits; can just let pts accept risk and skip trial Erdafitinib bladder "works well if you have disease.. we don't know... there are AEs" alectinib lung ...".. pemigatinib cholangio ... (Twitter) - Jun 12, 2020
- | Mekinist (trametinib) / Novartis, trametinib, Alecensa (alectinib) / Roche
Journal: cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. (Pubmed Central) - Jun 11, 2020
The data offer rationales for alectinib treatment in ALK expressing glioblastoma and for the use of ALK expression status as potential biomarker for alectinib treatment. In addition, the results propose MEK inhibition or radiotherapy as reasonable salvage treatments after acquired alectinib resistance.
- || Trial completion date, Trial primary completion date, Heterogeneity, PD(L)-1 Biomarker: DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (clinicaltrials.gov) - Jun 11, 2020
P2, N=119, Recruiting, Sponsor: University College, London
In addition, the results propose MEK inhibition or radiotherapy as reasonable salvage treatments after acquired alectinib resistance. Trial completion date: Jan 2023 --> Nov 2025 | Trial primary completion date: Jan 2023 --> Nov 2024
- |||||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical: .@peters_solange, of @CHUVLausanne, discusses updated data from the pivotal phase 3 ALEX trial, in which alectinib demonstrated a clinically meaningful improvement in OS compared with crizotinib in patients with ALK-positive NSCLC. #ASCO20 #lcsm https://t.co/NZUridmagB (Twitter) - Jun 9, 2020
- Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] Chugai Pharmaceutical Co., Ltd. () - Jun 9, 2020 - Abstract #BIO2020BIO_180;
Our proprietary products, such as anti-IL-6 monoclonal antibody Actemra®/RoActemra® (tocilizumab), ALK inhibitor Alecensa® (alectinib) and anti-FlXa/FX bispecific antibody Hemlibra® (emicizumab), those of which are now approved worldwide, illustrate our robust drug research and development capabilities. Chugai is also keen to collaborate with companies who has strong capability in drug discovery and cutting age technology.
- || Avastin (bevacizumab) / Roche, Alecensa (alectinib) / Roche
Enrollment open, Trial primary completion date, Combination therapy, Metastases: Alectinib in Combination With Bevacizumab in ALK Positive NSCLC (clinicaltrials.gov) - Jun 9, 2020
P2, N=40, Recruiting, Sponsor: Instituto Nacional de Cancerologia de Mexico
Chugai is also keen to collaborate with companies who has strong capability in drug discovery and cutting age technology. Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2020 --> Dec 2020
- | New P2 trial: PLATFORM Study of Precision Medicine for Rare Tumors (clinicaltrials.gov) - Jun 8, 2020
P2, N=624, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- || Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Clinical, Journal, HEOR: Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer. (Pubmed Central) - Jun 4, 2020
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2020 --> Dec 2020 Our results indicate that compared with crizotinib and alectinib, ceritinib is a cost-effective option for treatment-naïve patients with ALK-positive advanced NSCLC.
- ||||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical: The highly selective second-generation TKI alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non–small cell lung cancer. @peters_solange @CHUVLausanne #ASCO20 #lcsm https://t.co/lZ9eZsFMkP (Twitter) - Jun 4, 2020
- ||||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Just Out📣at @Annals_Oncology by @TonyMok9 ,our @OncoAlert 🚨colleague @peters_solange 👩⚕️ and team‼️ ✅Mature PFS data from the #ALEX study confirmed significant improvement in PFS for alectinib over crizotinib in #ALK positive #NSCLC #LungCancer #LCSM ‼️https://t.co/aGBupPPZi9 (Twitter) - Jun 1, 2020
- ||||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Updated OS and final PFS data of the ALEX trial of Alectinib vs Crizotinib in ALK+ NSCLC were presented in a poster discussion session at #ASCO20 by @peters_solange . The paper is now available #openaccess in Annals of Oncology https://t.co/ilPXVrVenM #LCSM @TonyMok9 (Twitter) - Jun 1, 2020
- |||| Alecensa (alectinib) / Roche
Clinical, HEOR, Gold Standard: This improved survival is also reinforced by the quality of life patients have on alectinib! I may be partial (it's a great name), but the ALEX trial remains my gold standard in ALK+ (Twitter) - May 31, 2020
- |||| Alecensa (alectinib) / Roche
Excellent 5 year OS results for 1st line alectinib in ALEX trial from @peters_solange. 62.5% 5-year survival, 34.9% still on alectinib! @alk_fusion @ALKLungCancer #lcsm #ASCO20 (Twitter) - May 31, 2020
- ||||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical: Different trials are ongoing evaluating the role of ALK TKIs as adjuvant treatment: Crizotinib in the ALCHEMIST and Alectinib in a Ph3 trial, recruiting to date. Great expectations! #LCSM (Twitter) - May 31, 2020
- ||| Retevmo (selpercatinib) / Eli Lilly, Alecensa (alectinib) / Roche
Clinical: And this will lead to exactly nothing. Except that we can be sure that future routine use of adjuvant alectinib, selpercatinib, etc. will be based on DFS results, maybe at 1 yr readout, if ppl even decide there's need to run randomized trials at all before using in early stage. (Twitter) - May 31, 2020
- ||||| Alecensa (alectinib) / Roche
Alectinib Continues to Maintain Significant OS Benefit in ALK+ NSCLC @peters_solange @CHUVLausanne @ASCO #ASCO20 #lcsm https://t.co/1aJCroNTgn (Twitter) - May 31, 2020
- |||| Alecensa (alectinib) / Roche
Post alectinib #alk #NSCLC setting to be explored further and driven by Mut profile #ASCO2020 ! (Twitter) - May 31, 2020
- ||| Tagrisso (osimertinib) / AstraZeneca, Alecensa (alectinib) / Roche
Clinical: A hypothetical question 💡 looking at those results, and the results of adjuvant osimertinib, and knowing there is adjuvant alectinib trial, too. Would you hope for/expect similar results from adjuvant alectinib? (Twitter) - May 31, 2020
- || Alecensa (alectinib) / Roche
Impressive data from #alectinib #ASCO20 (Twitter) - May 31, 2020
- ||||| Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
#ASCO20 Response to brigatinib (post-alectinib) noted in the presence of various #ALK resistance mutations including G1202R (1/3), L1196M (3/3), I1171N (1/2), I1171S (1/1). Well tolerated. Most common G3 tox were lipase (no pancreatitis), CK (no myalgias), HTN. #OncoAlert #LCSM (Twitter) - May 31, 2020
- |||| Xalkori (crizotinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
#ASCO20 Median PFS with brigatinib following alectinib (+/- prior crizotinib) was 7.3m. In 8pts with measurable CNS disease, intracranial RR 25% (63% SD). Updated analysis adds 1 response for ORR 34%, median duration of response of 11.8m! #OncoAlert #LCSM (Twitter) - May 31, 2020
- |||||| Xalkori (crizotinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
P2 data: #ASCO20 Abstract 9537 has results from J-ALTA, phase 2 trial of brigatinib (90mg qd x 1wk then 180mg qd) post-alectinib for #ALK NSCLC. Included 47pts who progressed on prior alectinib (+/- prior crizotinib) and RR 30%, DCR 79%, median time to response 1.9m. #OncoAlert #LCSM (Twitter) - May 31, 2020
- ||||| Alecensa (alectinib) / Roche
Clinical: This OS pattern for Alectinib in ALEX study of mets ALK-driven NSCLC is rivaling the overall survival of all stages resected NSCLC in curative treatment setting.... No??!! That's how AMAZING the data is!!! ✌👍👍👍💖💪🥳🏆🥇🎯 (Twitter) - May 30, 2020
- || Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
I am on Alectinib now changing to brigatinib...I have to stop Alectinib and start....but I have 2 opinions of when. One doctor said start the next day after stopping Alectinib and the other said to wait 3 days and then start Would you know anything about that? (Twitter) - May 30, 2020
- |||| Alecensa (alectinib) / Roche
#ASCO20 #LCSM Simply amazing looking through the updated OS analysis of ALEX trials presented by @peters_solange Impressive: to date, median OS not yet reached for Alectinib (HR 0.67 vs Crizo 57.6m) 5-yr survival 62.5% vs 45.5%, of course in favour of Alectinib That’s it! (Twitter) - May 30, 2020
- |||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
A GEM from our @OncoAlert 🚨Colleague @peters_solange Updated Survival Data from the ALEX study comparing Alectiniib to Crizotinib in 1⃣st line management of ALK+ #NSCLC OS for alectinib 5years 62.5%‼️ Tweet by our @OncoAlert Colleague @Jbauml (Twitter) - May 29, 2020
- ||||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Finally, @peters_solange presented updated survival data from the ALEX study, which compared alectinib to crizotinib in 1L management of ALK+ NSCLC. OS is quite impressive for alectinib (5 yr OS 62.5%!) but data remain immature #LCSM #ASCO20 (Twitter) - May 29, 2020
- || Alecensa (alectinib) / Roche
PK/PD data, Journal: Interactions of alectinib with human ABC drug efflux transporters and CYP450 biotransformation enzymes: effect on pharmacokinetic multidrug resistance. (Pubmed Central) - May 28, 2020
Our in vitro observations might serve as a valuable foundation for future in vivo studies that could support the rational for our conclusions and possibly enable providing more efficient and safer therapy to many oncological patients. SIGNIFICANCE STATEMENT: N/A.
- |||||| Alunbrig (brigatinib) / Takeda, Tagrisso (osimertinib) / AstraZeneca, Alecensa (alectinib) / Roche
Clinical: If we consider adjuvant osimertinib our new standard based on the ADAURA DFS HR 0.17 (#ASCO20), how far will we extrapolate? Will we see adjuvant alectinib/brigatinib in ALK+ NSCLC? Will we see use of osimertinib post chemoradiation (LAURA trial still ongoing)? #LCSM (Twitter) - May 28, 2020
- ||||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical: Or even ALK TKI plus MET TKI. Recent study showed almost a quarter of pts developed MET amp post Lorlatinib. And about 10 % after Alectinib. @alk_fusion #lcsm (Twitter) - May 28, 2020
- |||| Vitrakvi (larotrectinib) / Bayer, Eli Lilly, Alecensa (alectinib) / Roche
Next-Generation Sequencing: Using the same logic NGS is dangerous because people will start alectinib for ALK mutations and larotrectinib got NTRK mutations. Does it happen? Sure. Is the solution to stop doing NGS? Not even close (Twitter) - May 28, 2020
- ||| Rozlytrek (entrectinib) / Roche, Alecensa (alectinib) / Roche
Clinical, Next-Generation Sequencing: I think many of us don’t test in stage Ib-IIIa because not actionable outside clinical trial (ALCHEMIST). ADAURA may be first opportunity and thus would lead to testing. Am a bit worried that people will get NGS here and start using alectinib, entrectinib etc in adjuvant setting (Twitter) - May 28, 2020
- | Trial initiation date, Adverse events, Checkpoint inhibition: PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study (clinicaltrials.gov) - May 27, 2020
P=N/A, N=4724, Not yet recruiting, Sponsor: Sungkyunkwan University
SIGNIFICANCE STATEMENT: N/A. Initiation date: Apr 2020 --> Jul 2020
- | Alecensa (alectinib) / Roche
Enrollment closed: Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns (clinicaltrials.gov) - May 27, 2020
P=N/A, N=1, Active, not recruiting, Sponsor: Pfizer
Initiation date: Apr 2020 --> Jul 2020 Recruiting --> Active, not recruiting
- ||| Alecensa (alectinib) / Roche
Clinical: To their credit, Takeda is already doing a H2H versus alectinib in the 2L setting. A first line H2H right now is not all that compelling and I’d rather see combinations (chemo, etc). (Twitter) - May 24, 2020
- || Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
At least we saw the H2H trial of alectinib vs then SOC crizotinib, so there's that (Twitter) - May 24, 2020
- ||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
The CROWN trial comparing Lorlatinib with Alectinib, probably, will end sooner #LCSM (Twitter) - May 24, 2020
- || Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
It should be brigatinib to bear the burden of proving superior vs alectinib (Twitter) - May 24, 2020
- || Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Difficult to show that Alectinib is superior to Brigatinib, to date (Twitter) - May 24, 2020
- ||| Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Head-to-Head: Actually the company is doing a head to head phase 3 of brigatinib versus alectinib, first time I've seen this kind of chutzpah (ALTA3)! https://t.co/IrDOGJGh6e (Twitter) - May 24, 2020
- ||| Alecensa (alectinib) / Roche
I'd actually say "We should avoid cross-trial comparison when better data are available, but otherwise, they're the best data we have." If @TakedaOncology wants to compete in a market w/alectinib, let's see H2H trial...but companies don't like to test against true competition. (Twitter) - May 24, 2020
- |||| Xalkori (crizotinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
FDA event: Actually, we have four FDA-approved 1L for ALK: crizotinib, brigatinib, ceretinib, and alectinib. I agree, what we really need are more 2nd/3rd/4th line options. (Twitter) - May 24, 2020
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Journal: Qualitative and quantitative cytomorphologic features of primary anaplastic lymphoma kinase-positive lung cancer. (Pubmed Central) - May 23, 2020
Recruiting --> Active, not recruiting These results show that the cytomorphologic features of signet ring cells, nuclear grooves, and nucleoli shape can help to triage a small amount of cytologic and biopsy specimens for appropriate molecular testing of primary ALK (+) lung cancer.